TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") , which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback